Health Catalyst (HCAT) Q2 2026 Earnings Call Transcript
Health Catalyst (HCAT) reported Q2 2026 revenue of $70.5M, down 13% from $80.7M a year earlier. Technology revenue fell to $48.8M and professional services to $21.7M. The company completed the Vitalware divestiture for $147M cash and repaid about $160M of debt. FY2026 guidance: revenue $246M-$249M and adjusted EBITDA $18M-$18.5M.
How this was made
The 30-second read
Why it matters
The key tradable elements are the updated FY 2026 revenue and adjusted EBITDA guidance, the Q3 revenue and adjusted EBITDA ranges, and the quantified migration-related churn and at-risk ARR that inform retention and revenue durability.
Market read
Traders can update models for HCAT’s near-term revenue trajectory and margin path based on quantified churn, at-risk ARR retention expectations, and revised FY/Q3 guidance post-divestiture.
What to watch
The Ignite migration cost and timing of revenue recognition could create quarter-to-quarter volatility in technology gross margin, even if long-term margins trend higher.
Background
Health Catalyst held its Q2 2026 earnings call covering results for the quarter ended June 30, 2026, including the completed Vitalware divestiture and credit facility debt retirement.
Ticker impact
Health Catalyst reports Q2 2026 results and updates FY 2026 revenue and EBITDA guidance after completing the $147M Vitalware divestiture and retiring debt.
Near-term focus likely on Q3 revenue range and whether migration churn stabilizes; longer-term margin trajectory depends on technology mix and Ignite migration execution.
The article provides concrete financial datapoints (Q2 revenue decline, adjusted EBITDA, and updated FY/Q3 guidance) plus specific operational drivers (DOS-to-Ignite churn, at-risk ARR, and expected churn normalization by end-2027).
Market effects
Reinforces a healthcare analytics software theme: platform migrations can pressure near-term revenue via churn, while technology gross margin can improve with mix shift.
No clear regional spillover beyond US healthcare IT spending and vendor budgeting.
Limited, as the disclosures are company-specific and tied to its US-focused platform and client migrations.
Counterpoint
The guidance may look stable, but the disclosed $52M at-risk ARR and $12.5M notified down-sell/churn imply meaningful retention risk that could reappear in later quarters.
Key entities
- companyHealth Catalyst
Reports Q2 2026 financial results, completes Vitalware divestiture, retires credit facility debt, and updates FY 2026 and Q3 guidance.
- business_unitVitalware
Divested for $147M total cash consideration; migration and retention dynamics affect near-term revenue and ARR.
- counterpartyMed-Metrix
Transition Services Agreement provides up to six months of modest income offset after the Vitalware sale.
